Korea South
EDmicBio Inc., established in 2019 and headquartered in Korea South, is pioneering the frontier of 3D bioprinting technology. With the innovative mission to “Investigate your drug with 3D biomimicry, 3D organ-on-a-chip. We can build a better future for humans,” this startup expertly combines fields such as 3D organ-on-a-chip, stent development, bioink technology, and microfluidics.
The company's hallmark is its 3D bioprinting system, which facilitates the creation of intricate 3D Organ-on-a-chip models for drug toxicity assessment and personalized medicine. Moreover, EDmicBio Inc. is addressing critical medical challenges by developing biocompatible stents and highly specialized bioinks from various tissues.
The company secured a Seed Round from Digital Healthcare Partners on 22 December 2021, indicating early investor confidence. Operating within the Information Technology sector, EDmicBio Inc. presents promising potential for disrupting traditional biomedical processes, thus capturing significant attention from venture capitalists focused on cutting-edge biotech solutions.
